Key Details
Annual ROE
-98.96%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 23, 2023Recent annual earnings:
Feb 23, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with GBT included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Global Blood Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Global Blood Therapeutics?
- What is the ticker symbol for Global Blood Therapeutics?
- Does Global Blood Therapeutics pay dividends?
- What sector is Global Blood Therapeutics in?
- What industry is Global Blood Therapeutics in?
- What country is Global Blood Therapeutics based in?
- When did Global Blood Therapeutics go public?
- Is Global Blood Therapeutics in the S&P 500?
- Is Global Blood Therapeutics in the NASDAQ 100?
- Is Global Blood Therapeutics in the Dow Jones?
- When was Global Blood Therapeutics's last earnings report?
- When does Global Blood Therapeutics report earnings?
What is the primary business of Global Blood Therapeutics?
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.
What is the ticker symbol for Global Blood Therapeutics?
The ticker symbol for Global Blood Therapeutics is NASDAQ:GBT
Does Global Blood Therapeutics pay dividends?
No, Global Blood Therapeutics does not pay dividends
What sector is Global Blood Therapeutics in?
Global Blood Therapeutics is in the Healthcare sector
What industry is Global Blood Therapeutics in?
Global Blood Therapeutics is in the Biotechnology industry
What country is Global Blood Therapeutics based in?
Global Blood Therapeutics is headquartered in United States
When did Global Blood Therapeutics go public?
Global Blood Therapeutics's initial public offering (IPO) was on 12 August 2015
Is Global Blood Therapeutics in the S&P 500?
No, Global Blood Therapeutics is not included in the S&P 500 index
Is Global Blood Therapeutics in the NASDAQ 100?
No, Global Blood Therapeutics is not included in the NASDAQ 100 index
Is Global Blood Therapeutics in the Dow Jones?
No, Global Blood Therapeutics is not included in the Dow Jones index
When was Global Blood Therapeutics's last earnings report?
Global Blood Therapeutics's most recent earnings report was on 23 February 2023
When does Global Blood Therapeutics report earnings?
The date for Global Blood Therapeutics's next earnings report has not been announced yet